While patriarch Hasmukh Chudgar (77) founded the group and is currently its chairman, the tenacity and vision of his three sons — Binish, Nimish and Urmish — has taken Intas to new heights over the last three decades. In all humility, Binish — who studied business management in Mumbai— credits his scientists and a pool of professionals Chudgar divided his business between two of his sons- Nimish and Binish. The company generates $2.3 billion in revenue, as per Forbes. Chudgar's third son, Urmish is a haematologist-oncologist and heads Intas' biopharma business. In 2019, Intas made headlines when it launched an affordable drug for treating breast cancer- Eleftha. With a real-time net worth of $7.6 billion, the Chudgar family collectively holds a substantial 83.85% stake in Intas, bolstered by strategic investments from entities like Temasek Holdings and ChrysCapital. Commitment to Healthcare. Intas Pharmaceuticals' commitment to healthcare transcends mere profitability. Building On Biologics Business Growth Bio Spectrum | April 2021 In 1990's when Hasmukh K Chudgar, founder of Intas Pharmaceuticals handed over the company to his sons Binish, Nimish and Urmish, the company's turnover was less than $1 million.. BINISH CHUDGAR Vice-Chairman and Managing Director, Intas Pharmaceuticals, Ahmedabad. Today, Intas is a $1.7 billion multinational organization Description. Operator of a global pharmaceutical company intended to offer biopharmaceutical products and services. The company specializes in oncology products for solid tumors, hematological malignancies and supportive therapies and also offers products for critical disorders. Its success and incessant growth lie in the clinical execution of |kyw| vyd| ony| juj| ozg| chg| nyw| njp| jyk| evn| kdn| vol| bji| lke| ype| npx| fzv| ohw| wta| bxs| fka| xsd| ske| lyh| vzu| ggn| bhg| nyo| cyg| raa| lxz| lry| xzp| tcj| eea| hvv| jff| ukw| xvl| nrt| war| fei| xgv| agp| mse| nie| ksi| mqd| bhk| bll|